(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA set for first crewed moon return in over half a century - 2Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- 3Picking Childcare Administrations for Your Loved ones
- 4Pick Your Favored kind of books
- 5Zelensky names spy chief to head presidential office after corruption row
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- A definitive Manual for Internet Mastering and Expertise Improvement
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- Space Condos to Lift Your Metropolitan Living
- Doomed SpaceX Starlink satellite photographed from orbit
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
